Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Curcuminoids, the active compounds found in turmeric (Curcuma longa), have been studied for their anti-inflammatory and immunomodulatory properties, which are relevant to autoimmune disorders. Preclinical studies and some clinical trials suggest that curcuminoids can inhibit the activity of nuclear factor-kappa B (NF-κB) and other pathways involved in chronic inflammation and immune dysregulation. For example, research in animal models of rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease has shown improvements in disease markers, reduced tissue inflammation, and modulation of cytokine production following curcuminoid supplementation.

Human data is more limited but growing. Small randomized controlled trials and pilot studies have shown that curcumin supplementation may reduce disease activity and inflammatory markers in rheumatoid arthritis, ulcerative colitis, and other autoimmune conditions. However, these studies often have methodological limitations, such as small sample sizes, short durations, and variable formulations of curcuminoids (which can affect bioavailability). As a result, while there is promising evidence for the use of curcuminoids as adjunctive therapy in autoimmune disorders, more robust and larger clinical trials are needed to confirm efficacy and optimal dosing. The use of curcuminoids in this context is thus grounded in scientific rationale with moderate but not definitive evidence.

More about Curcuminoid
More about Autoimmune Disorders

Other ingredients used for Autoimmune Disorders

Other health conditions supported by Curcuminoid

Products containing Curcuminoid